About this episode

The episode discusses U.S. biotech policy, FDA updates, and major investments in China, featuring guest John Crowley from BIO.

On this week’s episode, Josh Schimmer, Sam Fazeli, Brian Skorney, and Yaron Werber kick off with a discussion on policy with special guest BIO’s CEO John Crowley, overviewing what it means for the U.S. to “win” the biotech race against China, emphasizing the need for innovation and ensuring access to medicines. The conversation shifts to the latest at the FDA, where John acknowledges concerns around consistency at the agency and expresses optimism following conversations with FDA leadership at the JP Morgan Healthcare conference earlier this month. Next, the co-hosts discuss major investments in China, including AstraZeneca’s $15B commitment to China through 2030, focusing on R&D, manufacturing, and partnerships. Shifting back to U.S. policy, the group addresses the growing measles outbreak, highlighting the belief that science, data, and policy pressure will win out over anti-science rhetoric. Next, John notes that codifying MFN would be devastating for the industry. The conversation turns to deals, with Merck’s decision not to acquire Revolution Medicines, noting that the company’s current strong cash position and recent deals will likely make them attractive to Big Pharma…

More episodes of Biotech Hangout

• Episode 180 - April 17, 2026 · April 17, 2026 · 54 min
• Episode 179 - April 10, 2026 · April 10, 2026 · 60 min
• Episode 178 - April 3, 2026 · April 3, 2026 · 1h 1m
• Episode 177 - March 27, 2026 · March 27, 2026 · 56 min
• Episode 176 - March 13, 2026 · March 13, 2026 · 1h 1m
• Episode 175 - March 6, 2026 · March 6, 2026 · 52 min

Explore listener stats, chart rankings, contacts and more on the Biotech Hangout podcast page.